March 2007. Volume 3. Number 1

Respiratory syncytial virus prophylaxis with monoclonal antibodies (palivizumab) in congenital cardiopathies: critical review of efficacy, effectiveness, efficiency and safety

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

MBE | Bases of evidence based medicine

Authors: González de Dios J1, Ochoa Sangrador C2, Balaguer Santamaría A3.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
3H General Catalunya. Sant Cugat del Vallés. Barcelona. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 24/02/2010
Acceptance date: 26/02/2007
Publication date: 01/03/2007

How to cite this article

González de Dios J, Ochoa Sangrador C, Balaguer Santamaría A. La profilaxis frente al virus respiratorio sincitial con anticuerpos monoclonales (palivizumab) en cardiopatías congénitas: revisión sistemática de la eficacia, efectividad, eficiencia y seguridad. Evid Pediatr. 2007;3:23.

MBE | Bases of evidence based medicine

Authors: González de Dios J1, Ochoa Sangrador C2, Balaguer Santamaría A3.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
3H General Catalunya. Sant Cugat del Vallés. Barcelona. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 24/02/2010
Acceptance date: 26/02/2007
Publication date: 01/03/2007

How to cite this article

González de Dios J, Ochoa Sangrador C, Balaguer Santamaría A. La profilaxis frente al virus respiratorio sincitial con anticuerpos monoclonales (palivizumab) en cardiopatías congénitas: revisión sistemática de la eficacia, efectividad, eficiencia y seguridad. Evid Pediatr. 2007;3:23.

References

  1. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infection in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126:212-9.
  2. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001;183:16-22.
  3. KingVJ, Viswanathan M, Bordley WC, Jackman AM, Sutton SF, Lohr KN, et al. Pharmacological treatment of bronchiolitis in infants and children: a systematic review. Arch Pediatr Adolesc Med. 2004;158:127-37.
  4. Christakis DA, Cowan CA, Garrison MM, Molteni R, Marcase E, Zerr DM. Variation in inpatient diagnostic testing and management of bronchiolitis. Pediatrics. 2005;115:878-84.
  5. Martinón Torres F, Rodríguez Núñez A, Martinón Sánchez JM. Bronquiolitis aguda: evaluación del tratamiento basado en la evidencia. An Esp Pediatr. 2001;55:345-54.
  6. González Caballero D, González Pérez-Yarza E. Bronquiolitis aguda: bases para un protocolo racional. An Esp Pediatr. 2001;55:355-64.
  7. Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care. 2003;48:209-31.
  8. Greenough A. Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Curr Opin Pulm Med. 2002;8:214-7.
  9. Bordley WC, Viswanathan M, King VJ, Sutton SF, Jackman AM, Sterling L, et al. Diagnosis and testing in bronchiolitis: a systematic review. Arch Pediatr Adolesc Med. 2004;158:119-26.
  10. Handforth J, Sharland M, Friedland JS. Prevention of respiratory syncytial virus infection in infants. BMJ. 2004;328:1026-7.
  11. Anónimo. Palivizumab: new indication. Moderate reduction in hospitalization rate. Prescrire Int. 2004;13:213-6.
  12. Heikkinen T, Valkonen H, Lehtonen L, Vainionpaa R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed. 2005;90:F64-8.
  13. Meissner HC. Uncertainty in the management of viral lower respiratory tract disease. Pediatrics. 2001;108:1000-3.
  14. Danés Carreras I, Arnaua de Bolós JM. Profilaxis de las infecciones por el virus respiratorio sincitial con palizumab. An Es Pediatr. 2002;56:289-91.
  15. González de Dios J, Ochoa C. Fármacos biotecnológicos, farmacoeconomía y asistencia sanitaria basada en pruebas. An Pediatr (Barc). 2004;60:207-11.
  16. Clemente Bautista S, Mendante Barrenechea L, Montoro Ronsano JB. Marco actual de los productos biotecnológicos según los estudios farmacoeconómicos disponibles. Med Clin (Barc). 2003;120:498-504.
  17. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. IMpact-RSV Study Group. Pediatrics. 1998;102:531-7.
  18. Sorrentino M, Powers T and The Palivizumab Outcomes Study Group. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect Dis J. 2000;19:1068-71.
  19. Lacaze-Masmonteil T, Roze JC, Fauroux B; French Pediatricians' Group of Synagis Patients' Name-Based Programs. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis. Pediatr Pulmonol. 2002;34:181-8
  20. Lacaze-Masmonteil T, Truffert P, Pinquier D, Daoud P, Goldfarb G, Vicaut E, et al. Lower respiratory tract illness and RSV prophylaxis in very premature infants. Arch Dis Child. 2004;89:562-7.
  21. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child. 2000;83:313-6.
  22. Oh PI, Lanctjt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P; The Composs Investigators. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J. 2002;21:512-8.
  23. Vogel AM, Lennon DR, Broadbent R, Byrnes CA, Grimwood K, Mildenhall L, et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J Paediatr Child Health. 2002;38:550-4.
  24. Henckel E, Luthander J, Berggren E, Kapadia H, Naver L, Norman M, et al. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockolm infant population, 1999 through 2002. Pediatr Infect Dis J. 2004;23:27-31.
  25. Pedraz C, Carbonell Estrany X, Figueras Aloy X, Quero J, and The Iris Study Group. Effect of palivizumab phrophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22:823-7.
  26. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104:419-27.
  27. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks- gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154:55-61.
  28. Lofland JH, O´Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther. 2000;22:1357-69.
  29. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health. 2000;36:422-7.
  30. Simpson S, Burls A. A systematic review of the effectiveness and cost-effectiveness of palivizumab (SynagisR) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. West Midlands Health Technology Assessment Group. Department of Public Health and Epidemology. University of Birmighan. 2001
  31. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants. A systematic review. Arch Pediatr Adolesc Med. 2002;156:1034-41.
  32. Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, et al. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health. 2002;38:352-7.
  33. Farina D, Rodríguez SP, Bauer G, Novali L, Bouzas L, González H, et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr Infect Dis J. 2002;21:287-91.
  34. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid´s high-risk children. Arch Pediatr Adolesc Med. 2002;156:1251-5.
  35. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalization in premature infants in Germany. Eur J Pediatr. 2003;162:237-44.
  36. Rietveld E, De Jonge HCC, Polder JJ, Vergouwe Y, Veexe HJ, Moll HA, et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J. 2004;23:523-9.
  37. Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F. Cost-effectiveness of respiratory syncitial virus prophylaxis with Palivizumab. J Pediatr Child Health. 2006;42:253-8.
  38. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006 ;332(7543):699-703. Epub 2006 Feb 22.
  39. Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infants. Is it worth it?. Arch Dis Child Fetal Neonatal Ed. 2005;90:F286-9.
  40. García-Guereta Silva L. Bronquiolitis en el lactante con cardiopatía congénita. Epidemiología y prevención. Rev OFIL. 2005;15:35-47.
  41. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982;307:397-400.
  42. Navas L, Wang E, De Carvalho V, Robinson J. Pediatric Investigators Collaborative Network on Infections in Canada: improved outcome of respiratory syncytial virus infection in a high-risk hospitalizad population of canadian children. J Pediatr. 1992;121:348-54.
  43. Moler FW, Khan AS, Meliones JN, Custer JR, Palmesano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med. 1992;20:1406-13.
  44. Khongphatthanayothin A, Wong PC, Samara Y, Newth CJL, Wells WJ, Starnes VA, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med. 1999;27:1974-81.
  45. Altman CA, Englund JA, Demmler G, Drescher KL, Alexander MA, Watrin C, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol. 2000;21:433-8.
  46. Fleming DM, Pannell RS, Cross KW. Mortality in children from influenza and respiratory syncytial virus. J Epidemiol Community Health. 2005;59:586-90.
  47. Cabalka AK. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J. 2004;23(Suppl 1):S41-5.
  48. Feltes TF, Cabalka AK, Meissner C, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-40.
  49. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442-6.
  50. Canadian Paediatric Society. Use of palivizumab in children with congenital heart disease. Paediatr Child Health. 2003;8:631-3
  51. Tulloh R, Marsh M, Blackburn M, Casey F, Lenney W, Weller P, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young. 2003;13:420-3.
  52. Chantepie A, Bureau de la Filiale de Cardiologie Pediatrique de la Société Française de Cardiologie. [Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society]. Arch Pediatr. 2004;11:1402-5.
  53. Aebi C, Barazzone C, Günthardt J, Hammer J, Kind C, Nadal D, et al. Konsensus statement zur praevention von respiratory syncytial virus (RSV)-infektionen mit dem humanisierten monoklonalen antikörper palivizumab (SynagisR). Paediatrica. 2004;15:12-16
  54. Nakazawa M, Saji T, Ichida F, Oyama K, Harada K, Kusuda S. Guidelines for the use of palivizumab in infants and young children with congenital heart diseases. Pediatr Intern. 2006;48:190-3.
  55. Suárez Cabrera P, Malo Concepción P, Maroto E, Santos de Soto J. Recomendaciones para la prevención de la infección por virus respiratorio sincitial en pacientes con cardiopatía congénita. [en línea] (consultado: 16/02/2007]. Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas. Disponible en: http://www.secardioped.org
  56. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodríguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524-30.
  57. Simoes EAF, Sondheimer HM, Top FH Jr, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr. 1998;133:492-9.
  58. Guyatt GH, Sackett FL, Cook DJ. User´s guides to the medical literature. II. How to use an article about therapy or prevention: A. Are the results of the study valid? JAMA. 1993;270:2598-2601.
  59. Guyatt GH, Sackett FL, Cook DJ. User´s guides to the medical literature. II. How to use an article about therapy or prevention: B. What are the results and will they help me in caring for my patients? JAMA. 1994;271:59-63.
  60. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalizations in haemodynamically significant congenital heart disease. Arch Dis Child. 2004;89:961-5.
  61. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865-70.
  62. Eriksson M, Bennett R, Rotzen-Ostlund M, Von Sydow M, Wigart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002;91:593-8.
  63. Feltes TF, Simoes E. Palivizumab prophylaxis in haemodinamically significant congenital heart disease. Arch Dis Child. 2005;90:875-6.
  64. Aebi C. Palivizumab prophylaxis in haemodinamically significant congenital heart disease. Author´s reply. Arch Dis Child. 2005;90:876-7.
  65. Meberg A, Bruu AL. Respiratory syncitial virus infections in congenital heart defects – hospitalizations and costs. Acta Paeditr. 2006;95:404-6.
  66. Prais D, Schonfeld T, Amir J, for the Israeli RSV Monitoring Group. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: A national survey before palivizumab use. Pediatrics. 2003;112:548-52.
  67. Prais D, Danino D, Schonfeld T, Amir J, for the Israelí RSV Monitoring Group. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis. A national survey. Chest. 2005;128:2765-71.
  68. González de Dios J, Ochoa Sangrador C. La profilaxis frente al virus respiratorio sincitial con anticuerpos monoclonales (palivizumab). Una panorámica a través de la Medicina basada en la evidencia. Rev Esp Pediatr. 2003;59:391-402.
  69. Ochoa C. González de Dios J. Outcomes of severity in the Impact Study: statistics by admission. Pediatrics (revista electrónica). 2003; vol 112. [consultado: 12/01/2004]. Disponible en: http:// pediatrics.aapublications.org/ cgi/eletters/112/3/548.
  70. Lanari M, Rossi GA, Merilla R, Di Luzio Paparatti U. High risk of nosocomial-acquired RSV infection in children with congenital heart disease. J Pediatr. 2004;145:140-1.
  71. Wu SY, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics. 2004;114:e554-e556.
  72. Manzoni P, Sala U, Gomirato G, Coscia A, Fabris C. Optimal timing and dosing intervals of palivizumab in premature neonates: still some work to do. Pediatrics. 2005;115:1439-40.
  73. Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before discharge: what is the evidence for its benefit?. Clin Ther. 2004;26:2130-7.
  74. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics. 2004;114:1606-11.
  75. Nuijten MJC, Wittenberg W, Lebmeier M. Cost effectiveness of Palivizumab for respiratory syncitial virus prophylaxis in high-risk children. A UK analysis. Pharmacoeconomics. 2007;25:55-71.
  76. Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol Young. 2005;15:251-5.
  77. Groothuis JR. Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Pediatr Infect Dis J. 2001;20:628-30.
  78. Lacaze-Masmonteil T, Seidenberg J, Mitchell I, Cossey V, Cihar M, Csader M, et al. Evaluation of the safety of Palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf. 2003;26:283-91.
  79. Null Jr D, Pollara B, Dennehy PH, Steichen J, Sánchez PJ, Givner LB, et al. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J. 2005;24:1021-3.
  80. Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported adverse drug events in infants and children under 2 year of age. Pediatrics. 2002;110:e53.
  81. Moore TJ, Weiss SR, Blaisdell CR. Reported fatal and serious adverse reactions associated with palivizumab. [en línea] Pediatric Academic Societies, 2002 (abstract). (consultado 05/08/2005). Disponible en: http:// www. pasmeeting.org/2002baltimore/latebreaker_files/lbabstracts.htm#7062.
  82. Mohan AK, Braun M, Ellenberg S, Hedje J, Coté TR. Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities. Pediatr Infec Dis J. 2004;23:342-5.
  83. Del Llano Señarís JE, Meneu de Guillerna R. Asistencia sanitaria basada en la evidencia. Med Clin (Barc). 1999;112(Supl 1):90-6.
  84. Del Llano Señarís JE, Oliva Moreno J. Medicina coste-efectiva y medicina basada en la evidencia: su impacto en el proceso de decisiones clínicas. Med Clin (Barc). 2000;114(Supl 3):34-41.
  85. Sunnegardh J. Prophylaxis with palivizumab against respiratory syncytial virus infections in infants with congenital heart disease – who should receive it?. Acta Paediatr. 2006;95:388-90.
  86. Soto Álvarez J. Inclusión de análisis farmacoeconómicos en ensayos clínicos: principios y prácticas. Med Clin (Barc). 2003;120:227-35.
  87. Bonillo Perales A. Bronquiolitis: necesidad de consenso asistencial. An Esp Pediatr. 2001;55:297-9.
  88. Grupo de Hospitales Benazuza. Quimioprofilaxis con palivizumab en Andalucía. Resultados de la epidemia de VRS 2000-2001. An Esp Pediatr. 2002;56:293-7.
  89. Lapeña López de Armentia S, Robles García MB, Martínez Baldás JP, Castañon Fernández L, Mallo Castaño B, Herrero Mendoza B, et al. Impacto potencial y análisis coste-eficacia de la profilaxis con palivizumab, en la prevención de la bronquiolitis, en prematuros menores de 33 semanas de gestación. An Pediatr (Barc). 2003;59:328-33.
  90. Bonillo Perales A, Díez-Delgado Rubio J, Ortega Montes A, Infante Márquez P, Jiménez Liria MR, Batllés Garrido J, et al. Antecedentes perinatales y hospitalización por bronquiolitis. Comparación con el Impact-RSV Study Group. An Esp Pediatr. 2000;53:527-32.
  91. Lapeña López de Armentia S, Castañon López L, Martínez Badás JP, Álvaro Iglesias E. Hospitalización por bronquiolitis aguda, edad de gestación y palivizumab. An Esp Pediatr. 2001;55:378.
  92. Salas Hernández S. Profilaxis con palivizumab frente al virus respiratorio sincitial: ¿es necesario revisar sus indicaciones?. An Pediatr (Barc). 2004;60:87-8.
  93. González de Dios J. Estudios de adecuación de la práctica clínica a la evidencia científica en la bronquiolitis: diagnóstico, tratamiento y prevención. Rev Esp Pediatr. 2004;60:395-6.
  94. González de Dios J, Ochoa Sangrador C. Palivizumab y bronquiolitis: necesidad de aplicar la eficiencia para adecuar la práctica clínica a las pruebas científicas. Med Clin (Barc). 2005;124:478-9.
  95. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IVIG. Pediatrics. 1998;102:1211-6.
  96. Carbonell Estrany X, Quero Jiménez J y Comité de Estándares de la Sociedad Española de Neonatología y Junta Directiva de la Sociedad Española de Neonatología. Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Esp Pediatr. 2000;52:372-4.
  97. Carbonell Estrany X, Quero Jiménez J y Comité de Estándares de la Sociedad Española de Neonatología. Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Esp Pediatr. 2002;56:334-6.
  98. Figueras Aloy J, Quero J, Doménech E, Herrera MC López Herrera, I Izquierdo, et al. Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Pediatr (Barc). 2005;63:357-62.
  99. Saji T, Nakazawa M, Harada K. Safety and efficacy of palivizumab prophylaxis in children with congenital heart disease. Pediatr Int. 2005;47:397-403.
  100. Rietveld E, Vergouwe Y, Steyerberg EW, Huysman MWA, de Groot R, Moll HA, for the RSV Study Group Southwest Netherlands. Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule. Pediatr Infect Dis J. 2006;25:201-7.
  101. Afghani B, Ngo T, Leu SY, Wu FL, Cecilio M, Aron-Johnson P, et al. The effect of an interventional program of adherence to the American Academy of Pediatrics Guidelines for palivizumab prophylaxis. Pediatr Infect Dis J. 2006;25:1019-1024.
  102. Ortiz Movilla R, Álvarez Fernández B, Martínez Bernat L, Iglesias González-Nicolás E, Muro Brussi M. Epidemiología y prevención del virus respiratorio sincitial. Rev Pediatr Aten Primaria. 2006;8:627-40.
  103. Moler FW. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure?. Pediatrics. 1999;104:559-60.
  104. Prince AM, Jacobs RF.Prevention of respiratory syncytial virus infection in high risk infants. J Ark Med Soc. 2001;98:115-8.
  105. Fenton C, Scout LJ, Plosker GL. Palivizumab : a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs. 2004;6:177-97.
  106. Figueras Aloy J, Carbonell Estrany X, Quero J, for The IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23:815-20.
  107. Law BJ, Langley JM, Allen U, Paes B, Lee DSC, Mitchell I, et al. The Pediatric Investigators Collaborative Network on Infections in Canada Study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23:806-14.
  108. Carbonell-Estrany X, Figueras Aloy J, and the Infección Respiratoria por Virus Respiratorio Sincitial Study Group, and Law JB and the Pediatric Investigators Collaborative Network on Infections in Canada Study Group. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation. Different methods yield consistent findings. Pediatr Infect Dis J. 2004;23:S193-S201.
  109. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541-5.
  110. Sigurs N, Bjarnason R, Sugurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501-7.
  111. Piedimonte G, Simoes EA. Respiratory syncytial virus and subsquent asthma: one step closer to unravelling the Gordian knot?. Eur Respir J. 2002;20:515-7.
  112. Martínez FD. Respiratory syncytial virus bronchiolitis and the patogénesis of childhood asthma. Pediatr Infect Dis J. 2003;22(Suppl 2):76-82.
  113. Jafri HS, Chávez-Bueno S, Mejías A, Gómez AM, Ríos AM, Nassi SS, et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic infalmmatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis. 2004;189:1856-65.
  114. Mejías A, Chávez Bueno S, Ríos AM, Saavedra Lozano J, Fonseca Aten M, Harfield J, et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decrease lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Angents Chemother. 2004;48:1811-22.
  115. Mejías A, Chávez-Bueno S, Ríos AM, Fonseca-Aten M, Gómez AM, Jafri HS, et al. Asma y virus respiratorio sincitial. Nuevas oportunidades de intervención terapéutica. An Pediatr (Barc). 2004;61:252-60.
  116. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigubergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy ata ge 13. Am J Respir Crit Care Med. 2005;171:137-141.
  117. Everard ML. The relationship between respiratory syncytial virus infections and the development of wheezing and asthma in children. Curr Opin Allergy Clin Immunol. 2006;6:56-61.
  118. Sáez-Llorens X, Moreno MT, Ramilo O, Sánchez PJ, Top FH Jr, Connor EM, for the MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23:707-12.
  119. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917-28.
  120. Papadopoulos NG, Moustaki M, Tsolia M, Bossios A, Astra E, Prezerakou A, et al. Association of rhinovirus infection with increased disease severity in acute bronchiolitis. Am J Respir Crit Care Med. 2002;165:1285-9.
  121. Fleming DM, Pannell RS, Elliot AJ, Cross KW. Respiratory illness associated with influenza and respiratory syncytial virus infection. Arch Dis Child. 2005;90:741-6.
  122. Iwane MK, Edwards KM, Szilagyi PG, Walter FJ, Griffin MR, Weinberg GA, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics. 2004;113:1758-64.
  123. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: a systematic review. BMJ. 2006;333(7572):782. Epub 2006 Oct 6.
  124. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167-70.
  125. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-65.
01/03/2007

Linked Comment